Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer

In recent years, there have been significant advances in the treatment of breast cancer resulting in remarkably high survival rates. However, treatment options for metastatic triple negative breast cancer (TNBC) are quite limited due to a lack of identifiable, unique markers. Using a phage display-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalscheuer, Stephen, Khanna, Vidhi, Kim, Hyunjoon, Li, Sihan, Sachdev, Deepali, DeCarlo, Arthur, Yang, Da, Panyam, Jayanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713791/
https://www.ncbi.nlm.nih.gov/pubmed/31462656
http://dx.doi.org/10.1038/s41598-019-48993-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713791/
https://www.ncbi.nlm.nih.gov/pubmed/31462656
http://dx.doi.org/10.1038/s41598-019-48993-6

Ejemplares similares